JH
Therapeutic Areas
Celularity Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Placental-derived biomaterial products | Wound care / Tissue regeneration | Approved/Commercial |
| MLASC-based therapies | Degenerative Diseases | Phase 1/2 |
| NK Cell therapies | Oncology | Phase 1/2 |
| T Cell therapies | Immunology/Oncology | Phase 1/2 |
Leadership Team at Celularity
RJ
Robert J. Hariri
Chairperson, Founder, and Chief Executive Officer
SB
Stephen Brigido
President, Degenerative Diseases
AG
Anna Gosiewska
R&D, Degenerative Diseases
SK
Sharmila Koppisetti
Clinical Development Immunology & Drug Safety
CP
Carmine Palummo
Corporate Operations
TW
Tim Wilk
Technical Operations
PD
Peter Diamandis
Director
GS
Geoffrey Shiu Fei Ling
Director
DP
Diane Parks
Director
VL
Vincent LeVien
Director